A 2026 Review argues that osteosarcoma survival and lung spread depend on stage-specific rewiring of extracellular-matrix ...
A focused preclinical review finds that natural products can suppress NRF2-linked antioxidant defenses in hepatocellular ...
Scientists have identified a plant compound that reduced joint swelling and inflammation in rats with experimental arthritis. The discovery offers a potential new direction for rheumatoid arthritis ...
A natural compound extracted from a medicinal plant has shown surprising promise against rheumatoid arthritis. In rats, it ...
These data lend support for Faeth’s multi-node strategy, with two upcoming readouts: FTH-PIK-201 topline data in second-line advanced endometrial cancer by year-end 2026 and FTH-PIK-101 interim data ...
Scientists co-led by St. Jude Children's Research Hospital have identified a potential therapeutic vulnerability in some ...
Combining EP300 degradation with AKT inhibition slowed osteosarcoma growth and prolonged survival in preclinical mouse models ...
VIKTORIA-1 shows gedatolisib maintained strong PFS benefit over alpelisib in PIK3CA-mutant HR+/HER2− breast cancer, including ...
BridgeBio Oncology's total equity value of $226 million is lower than its liquid assets of $344.1 million as of June 30. See ...
Faeth Therapeutics announced presentation of preclinical data at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain, in a poster entitled ?Characterising the efficacy of ...
The herbal compound helped reduce joint swelling and cartilage damage in rats with experimental arthritis. Scientists have ...
The Oct. 23 poster covers PIKTOR alone and with fulvestrant, oral SERDs and CDK inhibitors; data are intended to inform the ongoing FTH-PIK-101 Phase 1b/2 trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results